NCT02978625 2026-04-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Bezmialem Vakif University
Boston University
National Institutes of Health Clinical Center (CC)